Valuation dashboard for Prelude Therapeutics Incorporated (PRLD) with P/E N/A, P/B 3.24, EV/EBITDA -5.13 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme.
Analysis Summary
Trailing-twelve-month margins: gross margin 98.3%, operating margin -300.6%, net margin -269.7%.
At the current price of $4.47, PRLD has negative trailing earnings (P/E not meaningful) and an ROE of -75.35%. Market capitalisation stands at $254M.
Balance sheet quality for PRLD: current ratio of 2.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 3.24 |
| EV / EBITDA | -5.13 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PRLD | Prelude Therapeutics Incorporated | $254M | 3.24 | -75.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $4.47 |
| Market Cap | $254M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -75.35% |
| Return on Invested Capital | -43.74% |
| Return on Assets | -31.94% |
| Gross Margin | 98.26% |
| Operating Margin | -300.56% |
| Net Margin | -269.75% |
Related companies: AVTX · CRBU · ENTA · EPRX · FHTX · IMRX · IVA
Explore sector: Healthcare · Biotechnology
More sections of PRLD: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks